BioGend Therapeutics

Founded in 2016, Biogend (Stock code: 6733.TW)  focuses on the development of advanced orthopedic products and is aiming to provide orthopedic medical services in all domains.
Our product, RevoCart, is the only one-step cartilage regeneration surgery in the world. It has been proved by phase III clinical trials that it can regenerate cartilage tissue and has been certified in Taiwan. A 2-year follow study showed that RevoCart can restore activity in patients with mild to moderate OA. It has been out licensed to partners in China and ASEAN;
Our product, Osteo-Inductive Factor (a rhBMP-2 product), can be applied to regenerate bones such as long bones, spine, and tooth. Multi-national clinical trials are underway, and it has been out licensed to partners in Japan and China:
Biogend has professional teams in multi-functions. It's seeking high-potential technologies and assisting innovative product development through project management, providing one-stop CDMO services.